US Benign Prostatic Hyperplasia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$5.64 BnPlaceholder estimate
Estimate 2025$5.89 Bn43.7% of the global market
Projected 2034$8.60 Bn 46.1%Adds $2.71 Bn over 9 forecast years
CAGR 2025–20344.3%Faster than 17% of 173 Medical Devices markets here
Key players5
US is 43.66% of the global market.
In North America, the largest is US (this report) at $5.89 Bn.
48 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Benign Prostatic Hyperplasia Treatment Market Analysis Executive Summary
Benign prostatic hyperplasia treatments ease urinary problems from an enlarged prostate with medicines and minimally invasive procedures.
Key segments of the benign Prostatic Hyperplasia Treatment market include treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors and Prostatic Urethral Lift) and setting (Hospitals, Urology Clinics and Ambulatory Surgery Centers).
US Benign Prostatic Hyperplasia Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Benign Prostatic Hyperplasia Treatment Market Dynamics
Market Growth Drivers
An ageing male population, more men seeking care, less invasive procedures and telehealth for sensitive conditions are driving the benign Prostatic Hyperplasia Treatment market.
Opportunity
Office-based procedures, direct-to-consumer telehealth and wider insurance coverage give the benign Prostatic Hyperplasia Treatment market room to grow.
Market Restraints
Stigma, out-of-pocket costs and limited reimbursement for some procedures hold back the benign Prostatic Hyperplasia Treatment market.
Competitive Landscape for Benign Prostatic Hyperplasia Treatment Market in US
The benign Prostatic Hyperplasia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Benign Prostatic Hyperplasia Treatment Market in US
Benign Prostatic Hyperplasia Treatment in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 48 studies on Benign Prostatic Hyperplasia Treatment that are recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how benign Prostatic Hyperplasia Treatment products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Boston Scientific
7.2 Teleflex
7.3 Olympus Corporation
7.4 Procept BioRobotics
7.5 Astellas Pharma
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The benign Prostatic Hyperplasia Treatment market can be segmented based on various criteria, including treatment, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Benign Prostatic Hyperplasia Treatment right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Benign Prostatic Hyperplasia Treatment in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
How big is the Benign Prostatic Hyperplasia Treatment market in the US?
Placeholder estimate: about $5.89 Bn in 2025, rising to about $8.60 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Benign Prostatic Hyperplasia Treatment market in the US growing?
Placeholder estimate: about 4.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Benign Prostatic Hyperplasia Treatment market report cover?
The report splits the market by treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, Prostatic Urethral Lift, Water Vapor Therapy and more), setting (Hospitals, Urology Clinics, Ambulatory Surgery Centers) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Benign Prostatic Hyperplasia Treatment market?
Key players include Boston Scientific Corporation, Teleflex Inc, Olympus Corporation, Procept BioRobotics and Astellas Pharma Inc..
What is driving the Benign Prostatic Hyperplasia Treatment market?
An ageing male population, more men seeking care, less invasive procedures and telehealth for sensitive conditions are driving the benign Prostatic Hyperplasia Treatment market.
Who regulates Benign Prostatic Hyperplasia Treatment in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Benign Prostatic Hyperplasia Treatment are running in the US?
48 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Benign Prostatic Hyperplasia Treatment?
PubMed lists 26 papers on Benign Prostatic Hyperplasia Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US 
Canada
China
Japan
Germany
France
UK
Brazil
Italy
Spain
Saudi Arabia
Ecuador
Mexico
India
New Zealand
Australia
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya